Skip to content
DataLookout
Menu

NCT07229768

Clinical Study of 177Lu-CTR-FAPI In the Treatment of Patients With Advanced, Metastatic Solid Tumors

StatusCompleted
PhaseEarly Phase 1
SponsorYan Xing
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 8 words
    • Trial completed
    • Primary completion date changed from estimate of Nov 30, 2026 to Oct 10, 2026
    • Site details revised
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

AE
Timeframe: From enrolment to 12 months after the first dose

Secondary (2)

Radiation Dosimetry
ORR

Arms and interventions

177Lu-CTR-FAPI Treatment ArmExperimental

Drugs: 177Lu-CTR-FAPI

Sites

1 site in 1 country

  • Shanghai General HospitalShanghai, China